Welcome to our dedicated page for Nexentis Technologies SEC filings (Ticker: NXTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nexentis Technologies Inc. filings document material events, stockholder voting matters, capital-structure changes, and Nasdaq-related approvals for the company’s common stock. Its recent Form 8-K disclosures include amendments affecting security-holder rights and the completed one-for-seven reverse stock split of the company’s common stock.
The company’s proxy materials describe proposals for reverse stock split authority and equity issuance approvals under Nasdaq Marketplace Rule 5635(d). Other filing categories include material agreements, capital-structure disclosure, board authority, quorum and voting results, and amendments to the company’s governing documents.
Nexentis Technologies Inc. entered into an amended and restated facility agreement with L.I.A. Pure Capital Ltd., increasing its credit facility from EUR 6,000,000 to EUR 10,000,000. The facility continues to finance projects, including EUR 2,000,000 earmarked for one project in Germany and the remainder for other projects subject to lender pre-approval.
The amendment also updates warrant terms. The lender’s existing five-year warrant to purchase 1,850,000 shares of common stock at an exercise price of $1.00 per share now includes an enhanced anti-dilution adjustment, adding a “price maintenance” provision that can reduce the exercise price and/or increase warrant shares if future securities are issued below the then-current exercise price.
Nexentis Technologies Inc. reported a much larger quarterly loss as it reshaped its business around oncology biotech and renewable energy projects. For the three months ended March 31, 2026, total assets were $16.4M and cash and cash equivalents were $4.3M.
The company posted an operating loss of $8.2M and a net loss of $6.6M, or $10.74 per basic share, driven mainly by a non‑cash goodwill impairment of $6.3M related to the MitoCareX oncology unit and higher share‑based compensation.
Nexentis closed the sale of its former Save Foods business, recognizing an $0.9M gain in discontinued operations, and received Voice Assist shares now valued at $1.7M. Management disclosed substantial doubt about the company’s ability to continue as a going concern beyond early 2027 without additional financing, despite having $6.5M of working capital and ongoing access to equity facilities.
Nexentis Technologies Inc. held a special shareholder meeting where investors approved several key proposals affecting its capital structure. As of the record date March 10, 2026, there were 5,111,362 common shares outstanding, each entitled to one vote, and 3,129,968 shares were represented, equal to about 61.23% of voting power.
Shareholders approved a reverse stock split amendment allowing the board to choose a ratio between 1-for-2 and 1-for-500, with 2,855,535 votes for and 272,430 against. They also approved issuing securities in one or more non-public offerings with up to a 20% discount to the market price under Nasdaq Rule 5635(d), by a vote of 2,230,497 for and 112,345 against.
In addition, shareholders approved potential issuance of common shares upon exercise of warrants that may be issued under an amendment to the company’s facility agreement with L.I.A. Pure Capital Ltd., with 1,789,433 votes for and 98,561 against. A proposal to permit adjournment of the meeting if more time were needed for votes also passed, supported by 2,949,940 votes.
Nexentis Technologies, Inc. is registering a shelf offering of up to $100,000,000 of common stock, preferred stock, subscription rights, debt securities, warrants and units subject to completion, dated April 16, 2026. Each tranche will be sold from time to time and described in a prospectus supplement.
Shares outstanding were 730,459 as of April 15, 2026. The prospectus states proceeds will be used for general corporate purposes, including working capital, capital expenditures, repayment of indebtedness, and acquisitions or strategic investments.
Nexentis Technologies Inc. is implementing a reverse stock split of its common stock at a one-for-seven ratio. On April 3, 2026, the company filed a Certificate of Amendment in Nevada to effect this change, which becomes effective on April 7 at 4:15 p.m. Eastern Daylight Time.
At the market open on April 8, 2026, the common stock will begin trading on the Nasdaq Capital Market on a post-split basis under the symbol “NXTS” with a new CUSIP. Every seven issued and outstanding shares of common stock will automatically combine into one share, with no change to the $0.0001 par value and fractional shares rounded up to the next whole share.
The reverse split will reduce the number of shares outstanding from 5,111,362 to approximately 730,309, with proportional adjustments to equity awards, convertible notes, and warrants. Authorized capital will remain at 495,000,000 common shares and 5,000,000 preferred shares, and each stockholder’s ownership percentage will stay essentially the same aside from de minimis rounding effects.
Nexentis Technologies, Inc. files its annual report outlining a major strategic shift into oncology drug discovery and renewable energy projects. The company completed the acquisition of MitoCareX Bio Ltd. in October 2025, making it a wholly owned subsidiary focused on mitochondrial-targeted therapies for cancers such as non-small cell lung and pancreatic cancer, using its proprietary MITOLINE™ computational platform.
Nexentis also expanded into European solar and battery storage through a February 2025 agreement to purchase 70% of SB Storage 1 S.R.L. alongside Solterra Renewable Energy. It exited its legacy post-harvest food business by transferring approximately 98% of Save Foods Ltd. to Voice Assist, Inc. in March 2026. As of June 30, 2025, non‑affiliate equity had a market value of $6,387,364, and as of March 31, 2026, 5,111,362 common shares were outstanding. The company, together with MitoCareX, operates with seven full-time and two part-time employees.
Nexentis Technologies Inc. reported the initial holdings of a major shareholder on a Form 3. Reporting person Lee Eun Young, identified as a ten percent owner, holds 479,651 shares of common stock directly. The filing records this ownership position and does not show any recent share purchases or sales.
Nexentis Technologies Inc. Schedule 13G: Eun Young Lee reports beneficial ownership of 479,524 shares of Common Stock, equal to 9.38% of the class based on 5,111,362 shares outstanding as of March 10, 2026. The filing shows sole voting and dispositive power over these shares and is signed by Eun Young Lee on March 23, 2026.
Nexentis Technologies Inc. has completed a strategic share exchange involving its majority-owned subsidiary Save Foods Ltd. and Voice Assist, Inc. On March 15, 2026, Nexentis transferred all of its Save Foods ordinary shares, representing approximately 98% of Save Foods’ issued and outstanding share capital, to Voice Assist.
In return, Nexentis received shares of Voice Assist common stock representing 19.99% of Voice Assist on a fully diluted basis, calculated immediately after closing. Nexentis also maintains a previously signed Services Agreement under which it provides advisory and related services to Voice Assist in exchange for deferred cash from future financings capped at $1,000,000, royalty consideration on defined “New Future Projects,” and a share of any “Ecolab Gross Proceeds.” The Services Agreement runs through calendar year 2026 with extension rights until all consideration is fully received.